Methicillin-resistant Staphylococcus aureus: the superbug

Giuseppe Ippolito, Sebastiano Leone, Francesco N. Lauria, Emanuele Nicastri, Richard P. Wenzel

Research output: Contribution to journalArticle

106 Citations (Scopus)

Abstract

Over the last decade, methicillin-resistant Staphylococcus aureus (MRSA) strains have emerged as serious pathogens in the nosocomial and community setting. Hospitalization costs associated with MRSA infections are substantially greater than those associated with methicillin-sensitive S. aureus (MSSA) infections, and MRSA has wider economic effects that involve indirect costs to the patient and to society. In addition, there is some evidence suggesting that MRSA infections increase morbidity and the risk of mortality. Glycopeptides are the backbone antibiotics for the treatment of MRSA infections. However, several recent reports have highlighted the limitations of vancomycin, and its role in the management of serious infections is now being reconsidered. Several new antimicrobials demonstrate in vitro activity against MRSA and other Gram-positive bacteria. Data from large surveys indicate that linezolid, daptomycin, and tigecycline are almost universally active against MRSA. This review will briefly discuss the epidemiology, costs, outcome, and therapeutic options for the management of MRSA infections.

Original languageEnglish
JournalInternational Journal of Infectious Diseases
Volume14
Issue numberSUPPL. 4
DOIs
Publication statusPublished - Oct 2010

Fingerprint

Methicillin-Resistant Staphylococcus aureus
Infection
Linezolid
Costs and Cost Analysis
Daptomycin
Methicillin
Glycopeptides
Gram-Positive Bacteria
Vancomycin
Staphylococcus aureus
Epidemiology
Hospitalization
Economics
Anti-Bacterial Agents
Morbidity
Mortality
Therapeutics

ASJC Scopus subject areas

  • Microbiology (medical)
  • Infectious Diseases

Cite this

Methicillin-resistant Staphylococcus aureus : the superbug. / Ippolito, Giuseppe; Leone, Sebastiano; Lauria, Francesco N.; Nicastri, Emanuele; Wenzel, Richard P.

In: International Journal of Infectious Diseases, Vol. 14, No. SUPPL. 4, 10.2010.

Research output: Contribution to journalArticle

Ippolito, Giuseppe ; Leone, Sebastiano ; Lauria, Francesco N. ; Nicastri, Emanuele ; Wenzel, Richard P. / Methicillin-resistant Staphylococcus aureus : the superbug. In: International Journal of Infectious Diseases. 2010 ; Vol. 14, No. SUPPL. 4.
@article{505a2df21c7c47e6a956b63fd2da6909,
title = "Methicillin-resistant Staphylococcus aureus: the superbug",
abstract = "Over the last decade, methicillin-resistant Staphylococcus aureus (MRSA) strains have emerged as serious pathogens in the nosocomial and community setting. Hospitalization costs associated with MRSA infections are substantially greater than those associated with methicillin-sensitive S. aureus (MSSA) infections, and MRSA has wider economic effects that involve indirect costs to the patient and to society. In addition, there is some evidence suggesting that MRSA infections increase morbidity and the risk of mortality. Glycopeptides are the backbone antibiotics for the treatment of MRSA infections. However, several recent reports have highlighted the limitations of vancomycin, and its role in the management of serious infections is now being reconsidered. Several new antimicrobials demonstrate in vitro activity against MRSA and other Gram-positive bacteria. Data from large surveys indicate that linezolid, daptomycin, and tigecycline are almost universally active against MRSA. This review will briefly discuss the epidemiology, costs, outcome, and therapeutic options for the management of MRSA infections.",
author = "Giuseppe Ippolito and Sebastiano Leone and Lauria, {Francesco N.} and Emanuele Nicastri and Wenzel, {Richard P.}",
year = "2010",
month = "10",
doi = "10.1016/j.ijid.2010.05.003",
language = "English",
volume = "14",
journal = "International Journal of Infectious Diseases",
issn = "1201-9712",
publisher = "Elsevier",
number = "SUPPL. 4",

}

TY - JOUR

T1 - Methicillin-resistant Staphylococcus aureus

T2 - the superbug

AU - Ippolito, Giuseppe

AU - Leone, Sebastiano

AU - Lauria, Francesco N.

AU - Nicastri, Emanuele

AU - Wenzel, Richard P.

PY - 2010/10

Y1 - 2010/10

N2 - Over the last decade, methicillin-resistant Staphylococcus aureus (MRSA) strains have emerged as serious pathogens in the nosocomial and community setting. Hospitalization costs associated with MRSA infections are substantially greater than those associated with methicillin-sensitive S. aureus (MSSA) infections, and MRSA has wider economic effects that involve indirect costs to the patient and to society. In addition, there is some evidence suggesting that MRSA infections increase morbidity and the risk of mortality. Glycopeptides are the backbone antibiotics for the treatment of MRSA infections. However, several recent reports have highlighted the limitations of vancomycin, and its role in the management of serious infections is now being reconsidered. Several new antimicrobials demonstrate in vitro activity against MRSA and other Gram-positive bacteria. Data from large surveys indicate that linezolid, daptomycin, and tigecycline are almost universally active against MRSA. This review will briefly discuss the epidemiology, costs, outcome, and therapeutic options for the management of MRSA infections.

AB - Over the last decade, methicillin-resistant Staphylococcus aureus (MRSA) strains have emerged as serious pathogens in the nosocomial and community setting. Hospitalization costs associated with MRSA infections are substantially greater than those associated with methicillin-sensitive S. aureus (MSSA) infections, and MRSA has wider economic effects that involve indirect costs to the patient and to society. In addition, there is some evidence suggesting that MRSA infections increase morbidity and the risk of mortality. Glycopeptides are the backbone antibiotics for the treatment of MRSA infections. However, several recent reports have highlighted the limitations of vancomycin, and its role in the management of serious infections is now being reconsidered. Several new antimicrobials demonstrate in vitro activity against MRSA and other Gram-positive bacteria. Data from large surveys indicate that linezolid, daptomycin, and tigecycline are almost universally active against MRSA. This review will briefly discuss the epidemiology, costs, outcome, and therapeutic options for the management of MRSA infections.

UR - http://www.scopus.com/inward/record.url?scp=78149280829&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78149280829&partnerID=8YFLogxK

U2 - 10.1016/j.ijid.2010.05.003

DO - 10.1016/j.ijid.2010.05.003

M3 - Article

C2 - 20851011

AN - SCOPUS:78149280829

VL - 14

JO - International Journal of Infectious Diseases

JF - International Journal of Infectious Diseases

SN - 1201-9712

IS - SUPPL. 4

ER -